Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Atrial fibrillation (AF), the most common sustained heart rhythm disorder, is becoming increasingly prevalent in the Western world. The number of people with AF in the United States is projected to roughly double by the year 2050, to an estimated 6-12 million. For many patients with AF, rate control with atrioventricular (AV) node blockers is a widely accepted therapeutic strategy. These agents control heart rate, thus preventing symptoms and systolic heart failure associated with tachycardia due to a rapid ventricular response to AF. Beta-blockers are widely accepted as first line agents for rate control in AF, especially when patients have concomitant hypertension (HTN), coronary artery disease, cardiomyopathies, or heart failure (HF). As a class, beta-blockers are among the most commonly prescribed cardiovascular medications.
Among patients with AF treated with beta-blockers, the heart rate (HR) response varies substantially. Sometimes, adequate rate control can be achieved by titration of the beta-blocker dose; but frequently, additional AV nodal blockers and/or digoxin are necessary. In some cases, adequate rate control cannot be achieved even with the simultaneous use of multiple AV nodal blockers, necessitating mechanical ablation of the AV node and permanent pacemaker implantation.
Patient-specific variables that influence the response to beta-blockers include comorbid conditions, weight, age, and level of physical activity. Ethnic differences in the response to beta-blockers for the treatment of HTN and HF are well-described. However, the contribution of genetic variants to beta-blocker efficacy in AF is unknown. We propose to study, using a candidate gene approach, the effect of genetic variants on heart rate response to beta-blockade in patients with AF.
| Condition | Intervention |
|---|---|
|
Atrial Fibrillation |
Drug: Atenolol |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation |
- Ventricular rate response during exercise. [ Time Frame: 1 day ] [ Designated as safety issue: No ]After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol.
| Estimated Enrollment: | 200 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | February 2015 |
| Estimated Primary Completion Date: | February 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Atenolol
Patients will undergo a standardized, graded exercise protocol before ank after receiving a dose of oral atenolol.
|
Drug: Atenolol |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects must be at least 18 years of age.
- Subjects must have a history of persistent AF currently treated with a rate control strategy.
- Subjects should be willing to give written, informed consent.
- Subjects must be willing and able to participate in the exercise protocol.
Exclusion Criteria:
- New York Heart Association Class III or IV heart failure.
- A history of heart failure induced by tachy-arrhythmia.
A history of coronary artery disease and the presence of at least one of the following:
- Canadian Class III or IV angina.
- Recent myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 6 months.
- Severe renal or hepatic impairment.
- Subjects who have a clinically significant allergy/intolerance to atenolol, including a history of beta-blocker induced bronchospasm.
- Females who are pregnant or nursing.
- History of severe AV node dysfunction/pacemaker dependence.
- Subjects who have a systolic blood pressure < 90 mm Hg or resting VR <50 or >120 per minute on the day of the study.
- Patients currently taking Vaughan-Williams Class I or III anti-arrhythmic drugs.
Contacts and Locations| United States, Tennessee | |
| Vanderbilt University Medical Center | Not yet recruiting |
| Nashville, Tennessee, United States, 37232 | |
| Contact: Matt J Kolek, M.D. 615-936-1713 matt.kolek@vanderbilt.edu | |
| Principal Investigator: Dawood Darbar, M.D. | |
| Sub-Investigator: Matt J Kolek, M.D. | |
More Information
Additional Information:
Publications:
| Responsible Party: | Matt Kolek, Fellow in Cardiovascular Disease, Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT01719367 History of Changes |
| Other Study ID Numbers: | Kolek 01 |
| Study First Received: | October 29, 2012 |
| Last Updated: | October 31, 2012 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by Vanderbilt University:
|
Baseline (pre-atenolol) Post-atenolol |
Additional relevant MeSH terms:
|
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Atenolol Anti-Arrhythmia Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Antihypertensive Agents |
Sympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013